04  /  01  /  2018

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

10  /  08  /  2017

Therapeutic targeting of PP2A

11  /  11  /  2014

Bisphosphonates inactivate human EGFRs to exert anti-tumor actions

06  /  01  /  2012

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response

12  /  21  /  2001

KLF6, a candidate tumor suppressor gene in prostate cancer

07  /  17  /  2018

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

10  /  28  /  2015

All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

12  /  16  /  2014

Repurposing of bisphosphonates for the prevention and therapy of non-small cell lung and breast cancer

02  /  01  /  2005

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk

04  /  01  /  1995

The apolipoprotein(a) gene is regulated by sex hormones and acute phase inducers in YAC transgenic mice

05  /  15  /  2017

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

01  /  07  /  2014

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition

01  /  23  /  2013

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival

07  /  01  /  2005

Targeted inhibition of the KLF6 splice variant KLF6SV1 suppresses prostate cancer growth and spread

09  /  01  /  1987

In Situ Augmentation of Class I Major Histocompatibility Antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma
Read all published papers from the Narla Lab here.
BE IN 
TOUCH

© 2018

University of Michigan Medical Center

Rogel Cancer Center, 3131

1500 E. Medical Center 

Ann Arbor, MI 48109

Office Phone:  (734) 763 - 4010

Rogel-Informal-white.png
This site was designed with the
.com
website builder. Create your website today.
Start Now